Literature DB >> 22585218

Plasma concentrations of posaconazole administered via nasogastric tube in patients in a surgical intensive care unit.

Dominic Störzinger1, Stephan Borghorst, Stefan Hofer, Cornelius J Busch, Christoph Lichtenstern, Georg Hempel, Markus A Weigand, Torsten Hoppe-Tichy.   

Abstract

Abdominal surgery may affect intestinal absorption and the resulting levels of posaconazole in the blood. We measured plasma posaconazole levels in surgical intensive care unit (SICU) patients and tried to develop a predictive population pharmacokinetics model. A total of 270 samples from 15 patients receiving posaconazole via nasogastric tube were measured by high-performance liquid chromatography (HPLC). SICU patients showed lower plasma drug concentrations, a higher apparent clearance, and a higher volume of distribution than those in hematology patients, possibly due to poor absorption.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22585218      PMCID： PMC3421608          DOI： 10.1128/AAC.06167-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection.

Authors:  A J Ullmann; O A Cornely; A Burchardt; R Hachem; D P Kontoyiannis; K Töpelt; R Courtney; D Wexler; G Krishna; M Martinho; G Corcoran; I Raad
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

2.  Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.

Authors:  Oliver A Cornely; Johan Maertens; Drew J Winston; John Perfect; Andrew J Ullmann; Thomas J Walsh; David Helfgott; Jerzy Holowiecki; Dick Stockelberg; Yeow-Tee Goh; Mario Petrini; Cathy Hardalo; Ramachandran Suresh; David Angulo-Gonzalez
Journal:  N Engl J Med       Date:  2007-01-25       Impact factor: 91.245

3.  Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.

Authors:  Andrew J Ullmann; Jeffrey H Lipton; David H Vesole; Pranatharthi Chandrasekar; Amelia Langston; Stefano R Tarantolo; Hildegard Greinix; Wellington Morais de Azevedo; Vijay Reddy; Navdeep Boparai; Lisa Pedicone; Hernando Patino; Simon Durrant
Journal:  N Engl J Med       Date:  2007-01-25       Impact factor: 91.245

4.  Omeprazole significantly reduces posaconazole serum trough level.

Authors:  Jan-Willem C Alffenaar; Sander van Assen; Tjip S van der Werf; Jos G W Kosterink; Donald R A Uges
Journal:  Clin Infect Dis       Date:  2009-03-15       Impact factor: 9.079

5.  The effect of gastric Acid on the absorption of posaconazole.

Authors:  Rupali Jain; Paul Pottinger
Journal:  Clin Infect Dis       Date:  2008-05-15       Impact factor: 9.079

6.  Posaconazole plasma concentrations in critically ill patients.

Authors:  John Ray; Lewis Campbell; Sam Rudham; Quoc Nguyen; Deborah Marriott
Journal:  Ther Drug Monit       Date:  2011-08       Impact factor: 3.681

7.  Effect of varying amounts of a liquid nutritional supplement on the pharmacokinetics of posaconazole in healthy volunteers.

Authors:  Gopal Krishna; Lei Ma; Donna Vickery; Xin Yu; Irene Wu; Edward Power; Eric Beresford; Steven Komjathy
Journal:  Antimicrob Agents Chemother       Date:  2009-09-08       Impact factor: 5.191

8.  Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers.

Authors:  Elizabeth S Dodds Ashley; Jay B Varkey; Gopal Krishna; Donna Vickery; Lei Ma; Xin Yu; Darshana Malavade; Megan Goodwin; John R Perfect; Eddie Power
Journal:  Antimicrob Agents Chemother       Date:  2009-05-11       Impact factor: 5.191

9.  Development and validation of a high-performance liquid chromatography assay for posaconazole utilizing solid-phase extraction.

Authors:  Dominic Störzinger; Stefanie Swoboda; Christoph Lichtenstern; Carsten Müller; Markus A Weigand; Torsten Hoppe-Tichy
Journal:  Clin Chem Lab Med       Date:  2008       Impact factor: 3.694

10.  Posaconazole in intensive care patients I: invasive fungal infections in surgical intensive care and case presentation.

Authors:  Dominic Störzinger; Christoph Lichtenstern; Stefanie Swoboda; Markus A Weigand; Torsten Hoppe-Tichy
Journal:  Mycoses       Date:  2008-09       Impact factor: 4.377
View more
  6 in total

1.  Evaluation of Voriconazole and Posaconazole Dosing in Patients With Thermal Burn Injuries.

Authors:  Kaitlin L Musick; Savannah L Jones; Ashlyn M Norris; Lauren J Hochstetler; Felicia N Williams; Brian P McKinzie
Journal:  J Burn Care Res       Date:  2022-07-01       Impact factor: 1.819

2.  Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis.

Authors:  Michael J Dolton; Roger J M Brüggemann; David M Burger; Andrew J McLachlan
Journal:  Antimicrob Agents Chemother       Date:  2014-09-08       Impact factor: 5.191

Review 3.  Pharmacokinetics and Pharmacodynamics of Posaconazole.

Authors:  Lu Chen; Elke H J Krekels; Paul E Verweij; Jochem B Buil; Catherijne A J Knibbe; Roger J M Brüggemann
Journal:  Drugs       Date:  2020-05       Impact factor: 9.546

4.  External evaluation of published population pharmacokinetic models of posaconazole.

Authors:  Shuqi Huang; Qin Ding; Nan Yang; Zexu Sun; Qian Cheng; Wei Liu; Yejun Li; Xin Chen; Cuifang Wu; Qi Pei
Journal:  Front Pharmacol       Date:  2022-09-30       Impact factor: 5.988

Review 5.  Clinical Pharmacokinetics of Second-Generation Triazoles for the Treatment of Invasive Aspergillosis and Candidiasis.

Authors:  Zorica Jović; Slobodan M Janković; Dejana Ružić Zečević; Dragan Milovanović; Srđan Stefanović; Marko Folić; Jasmina Milovanović; Marina Kostić
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-04       Impact factor: 2.569

6.  Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients.

Authors:  Fekade B Sime; Janine Stuart; Jenie Butler; Therese Starr; Steven C Wallis; Saurabh Pandey; Jeffrey Lipman; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.